RSV vaccine in pregnancy to protect babies
Part of Infections, Women’s health & pregnancy clinical trials.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and between about 24 and 36 weeks (based on local guidelines)
- You are generally healthy and not in active labor
- You are willing to have your baby join the study after birth
- You plan to deliver in a hospital or facility that can do study procedures
- You have not had a serious reaction to a vaccine before
- You avoid taking certain other investigational treatments during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to protect babies from RSV: a vaccine given to pregnant women, and an antibody shot given to newborns. Both are already approved—this study checks if using them together works better than either alone.
This trial tests if the RSVpreF vaccine given during pregnancy can help pass antibodies to the baby in women living with HIV. It may protect the infant from RSV, a common respiratory virus.
This study tests whether a second dose of the RSV vaccine during a new pregnancy protects you and your baby from RSV. If you received the RSVpreF or Abrysvo vaccine in a past pregnancy, you may be able to join.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
Hear when a new RSV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.